

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): February 23, 2016

**CELLDEX THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-15006**  
(Commission File Number  
Identification No.)

**13-3191702**  
(IRS Employer)

**Perryville III Building, 53 Frontage Road, Suite 220,  
Hampton, New Jersey**  
(Address of principal executive offices)

**08827**  
(Zip Code)

Registrant's telephone number, including area code: **(908) 200-7500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

Celldex Therapeutics, Inc. (the "Company") hereby announces that the Company's financial printer inadvertently submitted the Company's annual report on Form 10-K for the year ended December 31, 2015 (the "10-K") while preparing a test file. While the Company does not anticipate any substantive changes to this document, today's version of the 10-K should be disregarded and, as previously disclosed, the Company intends to release fourth quarter and year-end 2015 financial results and file its 10-K on Thursday, February 25, 2016 before the U.S. financial markets open. The Company's executives will host a conference call at 8:00 a.m. EST on February 25th to discuss 2015 financial and business results and to provide an update on key 2016 objectives.

2

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELLDEX THERAPEUTICS, INC.**

/s/ Anthony S. Marucci  
Name: Anthony S. Marucci  
Title: Chief Executive Officer

Dated: February 23, 2016

3